Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 696-704

  Hughes Large, Jennifer M ^a   Pang, Dominic K T ^a   Robson, Debra L ^a   Chan, Pak ^a   Toma, Jelena ^a   Borradaile, Nica M ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Fatty acids; Lipids; Metabolic syndrome; Obesity; Vascular disease

Indexed keywords

ACIFRAN; ANTILIPEMIC AGENT; FAT DROPLET; GPR109A PROTEIN; GPRA109B PROTEIN; MESSENGER RNA; MK 1903; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE; NICOTINATE PHOSPHORIBOSYLTRANSFERASE; NICOTINIC ACID; OLEIC ACID; PALMITIC ACID; PROTEIN; SIRTUIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; FATTY ACID METABOLISM; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LIPOTOXICITY; OXIDATION; PROTEIN EXPRESSION; RNA INTERFERENCE;

EID: 84910091883     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.090     Document Type: Article

References (59)

1. Creider J.C., Hegele R.A., Joy T.R. Niacin: another look at an underutilized lipid-lowering medication. Nat. Rev. Endocrinol. 2012, 8:517-528.
2. Investigators A.-H., Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., McBride R., Teo K., Weintraub W. Niacin in patients with low hdl cholesterol levels receiving intensive statin therapy. N.Engl. J. Med. 2011, 365:2255-2267.
3. Group HTC Hps2-thrive randomized placebo-controlled trial in 25 673 high-risk patients of er niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291.
4. Group H.T.C., Landray M.J., Haynes R., Hopewell J.C., Parish S., Aung T., Tomson J., Wallendszus K., Craig M., Jiang L., Collins R., Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N.Engl. J. Med. 2014, 371:203-212.
5. Lavigne P.M., Karas R.H. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J.Am. Coll. Cardiol. 2013, 61:440-446.
6. Digby J.E., Martinez F., Jefferson A., Ruparelia N., Chai J., Wamil M., Greaves D.R., Choudhury R.P. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by gpr109a dependent mechanisms. Arterioscler. Thromb. Vasc. Biol. 2012, 32:669-676.
7. Chai J.T., Digby J.E., Ruparelia N., Jefferson A., Handa A., Choudhury R.P. Nicotinic acid receptor gpr109a is down-regulated in human macrophage-derived foam cells. PloS One 2013, 8:e62934.
8. Lukasova M., Malaval C., Gille A., Kero J., Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor gpr109a expressed by immune cells. J.Clin. Invest. 2011, 121:1163-1173.
9. Wu B.J., Yan L., Charlton F., Witting P., Barter P.J., Rye K.A. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 2010, 30:968-975.
10. Wu B.J., Chen K., Barter P.J., Rye K.A. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation 2012, 125:150-158.
11. Tavintharan S., Woon K., Pek L.T., Jauhar N., Dong X., Lim S.C., Sum C.F. Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. Atherosclerosis 2011, 215:176-179.
12. Kaplon R.E., Gano L.B., Seals D.R. Vascular endothelial function and oxidative stress are related to dietary niacin intake among healthy middle-aged and older adults. J.Appl. Physiology 2014, 116:156-163.
13. Huang P.H., Lin C.P., Wang C.H., Chiang C.H., Tsai H.Y., Chen J.S., Lin F.Y., Leu H.B., Wu T.C., Chen J.W., Lin S.J. Niacin improves ischemia-induced neovascularization in diabetic mice by enhancement of endothelial progenitor cell functions independent of changes in plasma lipids. Angiogenesis 2012, (15):377-389.
14. Chen J., Cui X., Zacharek A., Jiang H., Roberts C., Zhang C., Lu M., Kapke A., Feldkamp C.S., Chopp M. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann. Neurol. 2007, 62:49-58.
15. Wende A.R., Symons J.D., Abel E.D. Mechanisms of lipotoxicity in the cardiovascular system. Curr. Hypertens. Rep. 2012, 14:517-531.
16. Kim J.A., Montagnani M., Chandrasekran S., Quon M.J. Role of lipotoxicity in endothelial dysfunction. Heart Fail. Clin. 2012, 8:589-607.
17. Symons J.D., Abel E.D. Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Rev. Endocr. metabolic Disord. 2013, 14:59-68.
18. Dagher Z., Ruderman N., Tornheim K., Ido Y. Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Circ. Res. 2001, 88:1276-1282.
19. Helies-Toussaint C., Gambert S., Roller P., Tricot S., Lacour B., Grynberg A. Lipid metabolism in human endothelial cells. Biochimica biophysica acta 2006, 1761:765-774.
20. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., Aoki T., Etoh T., Hashimoto T., Naruse M., Sano H., Utsumi H., Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase c-dependent activation of nad(p)h oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
21. Yamagishi S., Okamoto T., Amano S., Inagaki Y., Koga K., Koga M., Choei H., Sasaki N., Kikuchi S., Takeuchi M., Makita Z. Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Mol. Med. 2002, 8:179-184.
22. Stentz F.B., Kitabchi A.E. Palmitic acid-induced activation of human t-lymphocytes and aortic endothelial cells with production of insulin receptors, reactive oxygen species, cytokines, and lipid peroxidation. Biochem. biophysical Res. Commun. 2006, 346:721-726.
23. Staiger K., Staiger H., Weigert C., Haas C., Haring H.U., Kellerer M. Saturated, but not unsaturated, fatty acids induce apoptosis of human coronary artery endothelial cells via nuclear factor-kappab activation. Diabetes 2006, 55:3121-3126.
24. Chinen I., Shimabukuro M., Yamakawa K., Higa N., Matsuzaki T., Noguchi K., Ueda S., Sakanashi M., Takasu N. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese zucker diabetic fatty rats. Endocrinology 2007, 148:160-165.
25. Ciapaite J., van Bezu J., van Eikenhorst G., Bakker S.J., Teerlink T., Diamant M., Heine R.J., Krab K., Westerhoff H.V., Schalkwijk C.G. Palmitate and oleate have distinct effects on the inflammatory phenotype of human endothelial cells. Biochimica biophysica acta 2007, 1771:147-154.
26. Chai W., Liu Z. P38 mitogen-activated protein kinase mediates palmitate-induced apoptosis but not inhibitor of nuclear factor-kappab degradation in human coronary artery endothelial cells. Endocrinology 2007, 148:1622-1628.
27. Kim F., Pham M., Luttrell I., Bannerman D.D., Tupper J., Thaler J., Hawn T.R., Raines E.W., Schwartz M.W. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 2007, 100:1589-1596.
28. Kim J.E., Kim Y.W., Lee I.K., Kim J.Y., Kang Y.J., Park S.Y. Amp-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (aicar) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J.Pharm. Sci. 2008, 106:394-403.
29. Peter A., Weigert C., Staiger H., Rittig K., Cegan A., Lutz P., Machicao F., Haring H.U., Schleicher E. Induction of stearoyl-coa desaturase protects human arterial endothelial cells against lipotoxicity. Am. J. physiology. Endocrinol. metabolism 2008, 295:E339-349.
30. Maloney E., Sweet I.R., Hockenbery D.M., Pham M., Rizzo N.O., Tateya S., Handa P., Schwartz M.W., Kim F. Activation of nf-kappab by palmitate in endothelial cells. A key role for nadph oxidase-derived superoxide in response to tlr4 activation. Arteriosclerosis, thrombosis, Vasc. Biol. 2009, (29):1370-1375.
31. Hara N., Yamada K., Shibata T., Osago H., Hashimoto T., Tsuchiya M. Elevation of cellular nad levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J.Biol. Chem. 2007, 282:24574-24582.
32. Potente M., Ghaeni L., Baldessari D., Mostoslavsky R., Rossig L., Dequiedt F., Haendeler J., Mione M., Dejana E., Alt F.W., Zeiher A.M., Dimmeler S. Sirt1 controls endothelial angiogenic functions during vascular growth. Genes. Dev. 2007, 21:2644-2658.
33. Borradaile N.M., Pickering J.G. Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell. 2009, 8:100-112.
34. Ahmed K., Tunaru S., Offermanns S. Gpr109a, gpr109b and gpr81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol. Sci. 2009, 30:557-562.
35. Gordon E.S. Non-esterified fatty acids in the blood of obese and lean subjects. Am. J. Clin. Nutr. 1960, 8:740-747.
36. Soriguer F., Garcia-Serrano S., Garcia-Almeida J.M., Garrido-Sanchez L., Garcia-Arnes J., Tinahones F.J., Cardona I., Rivas-Marin J., Gallego-Perales J.L., Garcia-Fuentes E. Changes in the serum composition of free-fatty acids during an intravenous glucose tolerance test. Obes. (Silver Spring) 2009, 17:10-15.
37. Liang C.C., Park A.Y., Guan J.L. Invitro scratch assay: a convenient and inexpensive method for analysis of cell migration invitro. Nat. Protoc. 2007, 2:329-333.
38. de Boer V.C., de Goffau M.C., Arts I.C., Hollman P.C., Keijer J. Sirt1 stimulation by polyphenols is affected by their stability and metabolism. Mech. Ageing Dev. 2006, 127:618-627.
39. van der Veer E., Ho C., O'Neil C., Barbosa N., Scott R., Cregan S.P., Pickering J.G. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J.biological Chem. 2007, 282:10841-10845.
40. Assini J.M., Mulvihill E.E., Sutherland B.G., Telford D.E., Sawyez C.G., Felder S.L., Chhoker S., Edwards J.Y., Gros R., Huff M.W. Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in ldlr(-)/(-) mice. J.Lipid. Res. 2013, 54:711-724.
41. Menon R.M., Gonzalez M.A., Adams M.H., Tolbert D.S., Leu J.H., Cefali E.A. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J.Clin. Pharmacol. 2007, 47:681-688.
42. Menon R.M., Adams M.H., Gonzalez M.A., Tolbert D.S., Leu J.H., Cefali E.A. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int. J. Clin. Pharmacol. Ther. 2007, 45:448-454.
43. Revollo J.R., Grimm A.A., Imai S. The nad biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates sir2 activity in mammalian cells. J.Biol. Chem. 2004, 279:50754-50763.
44. Yoshino J., Mills K.F., Yoon M.J., Imai S. Nicotinamide mononucleotide, a key nad(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell. Metab. 2011, 14:528-536.
45. Sundaresan N.R., Samant S.A., Pillai V.B., Rajamohan S.B., Gupta M.P. Sirt3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of ku70. Mol. Cell. Biol. 2008, 28:6384-6401.
46. Hashimoto-Komatsu A., Hirase T., Asaka M., Node K. Angiotensin ii induces microtubule reorganization mediated by a deacetylase sirt2 in endothelial cells. Hypertens. Res. : Official J. Jpn. Soc. Hypertens. 2011, 34:949-956.
47. Bonezzi K., Belotti D., North B.J., Ghilardi C., Borsotti P., Resovi A., Ubezio P., Riva A., Giavazzi R., Verdin E., Taraboletti G. Inhibition of sirt2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia 2012, 14:846-854.
48. Mortuza R., Chen S., Feng B., Sen S., Chakrabarti S. High glucose induced alteration of sirts in endothelial cells causes rapid aging in a p300 and foxo regulated pathway. PloS One 2013, 8:e54514.
49. Hallows W.C., Lee S., Denu J.M. Sirtuins deacetylate and activate mammalian acetyl-coa synthetases. Proc. Natl. Acad. Sci. U S A 2006, 103:10230-10235.
50. Li X., Zhang S., Blander G., Tse J.G., Krieger M., Guarente L. Sirt1 deacetylates and positively regulates the nuclear receptor lxr. Mol. Cell. 2007, 28:91-106.
51. Rodgers J.T., Lerin C., Gerhart-Hines Z., Puigserver P. Metabolic adaptations through the pgc-1 alpha and sirt1 pathways. FEBS Lett. 2008, 582:46-53.
52. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., Lambert P.D., Mataki C., Elliott P.J., Auwerx J. Specific sirt1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell. Metab. 2008, 8:347-358.
53. Jung J.K., Johnson B.R., Duong T., Decaire M., Uy J., Gharbaoui T., Boatman P.D., Sage C.R., Chen R., Richman J.G., Connolly D.T., Semple G. Analogues of acifran: agonists of the high and low affinity niacin receptors, gpr109a and gpr109b. J.Med. Chem. 2007, 50:1445-1448.
54. Santolla M.F., De Francesco E.M., Lappano R., Rosano C., Abonante S., Maggiolini M. Niacin activates the g protein estrogen receptor (gper)-mediated signalling. Cell. Signal. 2014, 26:1466-1475.
55. Li X., Millar J.S., Brownell N., Briand F., Rader D.J. Modulation of hdl metabolism by the niacin receptor gpr109a in mouse hepatocytes. Biochem. Pharmacol. 2010, 80:1450-1457.
56. Boatman P.D., Lauring B., Schrader T.O., Kasem M., Johnson B.R., Skinner P., Jung J.K., Xu J., Cherrier M.C., Webb P.J., Semple G., Sage C.R., Knudsen J., Chen R., Luo W.L., Caro L., Cote J., Lai E., Wagner J., Taggart A.K., Carballo-Jane E., Hammond M., Colletti S.L., Tata J.R., Connolly D.T., Waters M.G., Richman J.G. (1ar,5ar)1a,3,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (mk-1903): a potent gpr109a agonist that lowers free fatty acids in humans. J.Med. Chem. 2012, 55:3644-3666.
57. Lombard D.B., Alt F.W., Cheng H.L., Bunkenborg J., Streeper R.S., Mostoslavsky R., Kim J., Yancopoulos G., Valenzuela D., Murphy A., Yang Y., Chen Y., Hirschey M.D., Bronson R.T., Haigis M., Guarente L.P., Farese R.V., Weissman S., Verdin E., Schwer B. Mammalian sir2 homolog sirt3 regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 2007, 27:8807-8814.
58. Chai J.T., Digby J.E., Choudhury R.P. Gpr109a and vascular inflammation. Curr. Atheroscler. Rep. 2013, 15:325.
59. Ganji S.H., Qin S., Zhang L., Kamanna V.S., Kashyap M.L. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009, 202:68-75.